Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Minority Interest (2018 - 2021)

Amphastar Pharmaceuticals has reported Minority Interest over the past 4 years, most recently at $45.2 million for Q2 2021.

  • Quarterly results put Minority Interest at $45.2 million for Q2 2021, changed N/A from a year ago — trailing twelve months through Jun 2021 was $45.2 million (changed N/A YoY), and the annual figure for FY2020 was $46.4 million, up 0.55%.
  • Minority Interest for Q2 2021 was $45.2 million at Amphastar Pharmaceuticals, roughly flat from $45.4 million in the prior quarter.
  • Over the last five years, Minority Interest for AMPH hit a ceiling of $46.4 million in Q4 2020 and a floor of $21.9 million in Q3 2018.
  • Median Minority Interest over the past 4 years was $45.3 million (2019), compared with a mean of $42.0 million.
  • Biggest five-year swings in Minority Interest: skyrocketed 102.47% in 2019 and later decreased 1.0% in 2021.
  • Amphastar Pharmaceuticals' Minority Interest stood at $31.9 million in 2018, then skyrocketed by 44.6% to $46.2 million in 2019, then grew by 0.55% to $46.4 million in 2020, then decreased by 2.56% to $45.2 million in 2021.
  • The last three reported values for Minority Interest were $45.2 million (Q2 2021), $45.4 million (Q1 2021), and $46.4 million (Q4 2020) per Business Quant data.